Pages that link to "Q69488293"
Jump to navigation
Jump to search
The following pages link to Anti-interleukin 2 receptor monoclonal antibody in the treatment of ongoing acute rejection episodes of human kidney graft--a pilot study (Q69488293):
Displaying 12 items.
- Immunosuppression through inhibition of interleukin-2/interleukin-2 receptor interaction (Q33541440) (← links)
- Current status of renal transplantation (Q33558294) (← links)
- Tumor necrosis factor production during human renal allograft rejection is associated with depression of plasma protein C and free protein S levels and decreased intragraft thrombomodulin expression (Q36230830) (← links)
- Nephrology, dialysis and transplantation (Q36683763) (← links)
- Use of monoclonal antibodies in human transplantation (Q36845422) (← links)
- A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation (Q40649309) (← links)
- Prophylactic use of the IL-2 receptor-specific monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplantation (Q45209716) (← links)
- Transplantation (Q68761759) (← links)
- [Monoclonal antibodies. Diagnostic and therapeutic use and prospects for the future] (Q70742207) (← links)
- Relevant targets for therapy with monoclonal antibodies in allograft transplantation (Q72822633) (← links)
- Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial (Q73585321) (← links)
- Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation (Q93911532) (← links)